Unknown Analyst's questions to Dr Reddy's Laboratories Ltd (RDY) leadership • Q4 2025
Question
An analyst from Quantum Mutual Fund asked about the drivers of UK revenue growth, whether the H2 NRT revenue could be annualized, the quarterly cadence for Revlimid sales in FY26, and the expected competitive intensity for semaglutide compared to past GLP-1 launches like liraglutide.
Answer
CEO Erez Israeli attributed UK growth to new product launches, including bevacizumab. He and Executive Richa Periwal confirmed that annualizing the H2 NRT revenue provides a reasonable run-rate. The CEO declined to give specific guidance on Revlimid's quarterly sales. He reiterated the belief that the semaglutide market will be very competitive over time and that the company is preparing for a high-volume, low-cost scenario.